b) Intravenous Glycoprotein IIb/IIIa inhibitors are useful if the patient goes to the cath lab

Yes

It was shown that a 29% reduction in 30 day mortality can be achieved with abciximab (Reopro) a IIb/IIIa inhibitor in patients going to the catheterization lab. (13) Eptifibatide (Integrilin) is also approved prior to mechanical angiographic intervention.

There may be more than one correct answer for this decision point.